OUR NEWS
August 26, 2026
Beyond Mutation-Only MRD: Making Better Use of ctDNA Data
After curative-intent treatment for solid tumors, molecular residual disease (MRD) testing is increasingly used to look for residual tumor signals that may not yet be visible on imaging. [1] Current ctDNA MRD strategies generally take one of two approaches. Some use tumor…
August 11, 2026
Geneseeq Expands PanTRKare™ with a Third NMPA-Approved CDx Application for VELMARTO® (Eratrectinib)
TORONTO, Canada - August 11, 2026 - Geneseeq Technology Inc., a global precision oncology company, announced that its PanTRKare™ NTRK1/NTRK2/NTRK3 Gene Fusion Detection Kit has received approval from China’s National Medical Products Administration (NMPA) as a companion…
July 14, 2026
Geneseeq Canada Named First Genomic Testing Partner in UHN’s SHERLOCK Study
Collaboration supports genomic profiling and molecular monitoring research within one of Canada’s largest prospective cancer genomics and molecular residual disease studies TORONTO, Canada – [July 14th,2026] – Geneseeq Technology Inc. (Geneseeq Canada) is pleased to…
November 10, 2025
Geneseeq Receives NMPA Approval for PanTRKare™ – China’s First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions
Toronto, Canada — [November 10, 2025] — Geneseeq Technology Inc., a global precision oncology company, today announced its PanTRKare™ NTRK1/NTRK2/NTRK3 Gene Fusion Detection Kit has received marketing authorization from China’s National Medical Products Administration…
September 29, 2025
Geneseeq Validates Cell-free DNA Blood Test for Early Detection of Pancreatic Cancer in a Prospective Study
Toronto, Canada – Geneseeq and its clinical collaborators have published a landmark study in Cancer Discovery showing that a simple cell-free DNA (cfDNA) blood test can detect pancreatic cancer at its early stages – often months before it becomes visible on imaging scans.…
September 2, 2025
GeneseeqPrime® Gains FDA 510(k) Clearance
With FDA., CE-IVD, and NMPA approvals, the comprehensive tumor profiling kit enables decentralized, standardized oncology testing worldwide Toronto, Canada – September 2, 2025 – Geneseeq Technology Inc. today announced that the U.S. Food and Drug Administration (FDA)…
May 28, 2025
Geneseeq’s Breakthrough Cancer Detection Blood Test Published in Nature Medicine
Large-Scale Study Confirms CanScan® Test Accurately Detects Early-Stage Cancers From a Simple Blood Draw Toronto, Canada – May 27, 2025 - Geneseeq is proud to announce the publication of results from its large-scale multi-cancer early detection (MCED) study in Nature…
May 21, 2025
Geneseeq Showcases Cutting-Edge Liquid Biopsy Research Across Multiple Cancer Types at ASCO 2025
[Toronto, May 21, 2025] - Geneseeq Technology Inc., shared today that 12 research studies have been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, underscoring the company’s continued innovation in cell-free DNA…
May 7, 2025
Geneseeq Unveils Groundbreaking Blood Test for Early Detection of Pancreatic Cancer
May 7, 2025– Geneseeq Technology Inc., in collaboration with leading clinical institutions, has developed a cutting-edge blood-based screening test that could transform early detection of pancreatic cancer-potentially saving by identifying the disease at more treatable…
April 9, 2025
Geneseeq Technology Inc. to showcase seventeen studies at 2025 American Association for Cancer Research (AACR) annual meeting
[Toronto, April 9, 2025] – More than just another cancer research conference, AACR 2025 is where translational science and clinical innovation converge. This year’s theme, “Unifying Cancer Science and Medicine,” highlights the growing impact of research that bridges the…
December 3, 2024
GENESEEQ’S NGS LIQUID BIOPSY KIT MARKS THE FIRST TO ENTER NMPA’S SPECIAL REVIEW AND APPROVAL OF INNOVATIVE MEDICAL DEVICE
Recently, the National Medical Products Administration (NMPA) announced that Geneseeq’s “EGFR/KRAS/MET Gene Mutation Detection Kit (Reversible Terminator Sequencing Method)” has entered the Special Review and Approval of Innovative Medical Device pathway. This marks the…
July 3, 2024
Geneseeq partners with Jiangsu Vcare PharmaTech to develop a CDx for NTRK inhibitor in China.
July 3, 2024, Toronto - Geneseeq Technology Inc. announced this week its partnership with Jiangsu Vcare PharmaTech to develop a companion diagnostic (CDx) kit and advance the product launch of Vcare’s pan-neurotrophic tyrosine receptor kinase (NTRK) inhibitor VC004 in…
May 14, 2024
Geneseeq AT ASCO 2024
The American Society of Clinical Oncology (ASCO) Annual Meeting stands as one of the most influential gatherings in clinical oncology, offering a critical platform for presenting clinical studies that have the potential to shape future practice and research. This year, ASCO…
March 6, 2024
Geneseeq to Showcase Twelve Studies at 2024 American Association for Cancer Research (AACR) Annual Meeting
[Toronto, March 6, 2024] – The AACR Annual Meeting is one of the most significant gatherings in the field of oncology, attracting leading scientists, clinicians, and industry professionals worldwide. This year's AACR 2024, taking place from April 5th to 10th in San Diego,…
January 3, 2024
FDA Grants Breakthrough Device Designation for Geneseeq’s Multi-cancer Early Detection Solution
Geneseeq announced that its multi-cancer early detection solution, CanScan™, has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA). CanScan™ utilizes low-depth whole-genome sequencing (WGS) on circulating cell-free DNA (cfDNA) from a…
October 17, 2023
Geneseeq to present four studies at ESMO 2023
Toronto, Oct.17th 2023-Geneseeq Technology Inc. is excited to share four collaborated studies at the 2023 European Society for Medical Oncology (ESMO) annual meeting from October.20th-24th at Madrid, Spain. Highlights of these studies include: A mini oral presentation on…
October 13, 2023
GENESEEQ RECEIVES CHINESE NMPA APPROVAL FOR LUNG CANCER TUMOR MUTATIONAL BURDEN NGS TEST KIT
Toronto Oct.13th –Geneseeq Technology Inc. announced on Thursday that Geneseeq’s Non-Small Cell Lung Cancer Tumor Mutational Burden Test Kit (Reversible terminator sequencing method) (NSCLC TMB Kit) has gained approval from the Chinese National Medical Products…
August 29, 2023
GENESEEQ TO SHARE EIGHT COLLABORATED STUDIES AT WCLC 2023
Geneseeq will share three mini-oral presentations and five poster studies at the World Conference on Lung Cancer (WCLC) 2023, which will be held on September 9-12th, 2023 in Singapore. These Geneseeq-collaborated studies cover novel prognostic and predictive biomarkers in…
August 22, 2023
Geneseeq Gains CE Marks for NGS-based Test Kits for Solid Tumors and Hematological Cancer
Toronto- Aug. 22nd- Geneseeq Technology Inc. has announced that three of our next-generation sequencing (NGS)-based cancer genetic testing kits, GENESEEQPRIME NGS Tumor Gene Detection Kit (GeneseeqPrime™), GENESEEQ Homologous Recombination Deficiency Detection Kit…
May 25, 2023
GENESEEQ TO SHOWCASE NEW FINDINGS AT ASCO 2023
Toronto, May 25- Geneseeq Technology Inc. is set to present four collaborative studies at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, scheduled to take place in Chicago from June 2nd to 6th. These studies, which will be presented both in-person and…
May 16, 2023
Geneseeq published new research on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer
TORONTO, May 16, 2023 – The majority of cancer-related deaths worldwide are caused by non-small-cell lung cancer (NSCLC), and even after the tumour has been surgically removed, between 30 to 55 percent of NSCLC patients experience a recurrence because of minimum residual…
April 13, 2023
Geneseeq co-publish with UHN on using ctDNA as a prognostic biomarker for immunotherapy
TORONTO, April 13, 2023 – Geneseeq co-published a study with Princess Margaret Cancer Centre in the JCO Precision Oncology journal, investigating the use of ctDNA as a prognostic biomarker for immunotherapy in early-phase clinical trials. Immunotherapy has shown promising…
April 11, 2023
Geneseeq to Present 13 Posters at AACR 2023
April 11, 2023-Geneseeq Technology Inc. is happy to share 13 collaborated studies at the 2023 American Association for Cancer Research (AACR) annual meeting from April.14th-19th in Orlando onsite and virtually. Highlights of these studies include: Data on Geneseeq’s new…
March 9, 2023
Geneseeq and Collaborators Initiate MOTION Study to Evaluate the Performance of Minimal Residual Disease Test SHIELDING™ in Early-stage Lung Cancer
March 09, 2023, Toronto - This week, Geneseeq Technology Inc. has announced the initiation of the MOTION study in collaboration with ten clinical sites to evaluate the performance of Geneseeq’s minimal residual disease test SHIELDING™ in patients with operable early-stage…
January 24, 2023
Geneseeq receives CE Marks for MRD and MCED tests.
TORONTO - Jan 24, 2023 - Geneseeq Technology Inc. announced that Geneseeq’s multi-cancer minimal residual disease detection (MRD) and multi-cancer early detection (MCED) kits were both CE Marked for liquid biopsy use in solid tumor patients. The markings will enable…
November 15, 2022
Geneseeq Publishes Promising Early Lung Cancer Detection Results in AJRCCM
TORONTO, Nov. 15, 2022 - Geneseeq Technology Inc. ("Geneseeq"), a company focused on advancing cancer genomic profiling through cutting-edge next-generation based technologies, today announced high-performing results from a lung cancer study testing the company's early…
November 3, 2022
Geneseeq study evaluates the clinical value of cell-free DNA 5’-end motif profile in the prediction of pathological complete response for LARC patients after neoadjuvant chemoradiotherapy
TORONTO, November 3, 2022 – In recent years, the 'Wait and Watch' (W&W) approach has been an alternative to surgery for locally advanced rectal cancer (LARC) patients after neoadjuvant chemoradiotherapy (nCRT). The W&W approach aims to prevent unessential surgery…
October 18, 2022
Geneseeq study highlights ctDNA monitoring clinical value in colorectal cancer patients resistant to BRAF/EGFR-targeted therapy
TORONTO, 18 Oct, 2022 – Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. Mutations in the BRAF oncogene of the MAPK pathway are present in 8-10% of cases. Metastatic CRC (mCRC) patients with BRAFV600E mutation carry a unique disease…
October 12, 2022
Interesting findings on ctDNA-based MRD detection in patients with resectable non-small cell lung cancer by Geneseeq
TORONTO, 12 Oct 2022 - Approximately 30% of non-small cell lung cancer (NSCLC) are non-metastatic and eligible for surgical resection with curative intent. Yet up to half of these patients developed recurrence and eventually lead to death despite curative resection.…
September 7, 2022
Geneseeq to present five posters at European Society for Medical Oncology 2022
With a mission to expand the boundaries of cancer care, the annual European Society for Medical Oncology (ESMO) Congress will be held both in person in Paris, France, and virtually on September 9th. The ESMO congress is a global gathering of oncology professionals to share…
August 3, 2022
GENESEEQ AND COLLABORATORS SHARE NEW FINDINGS AT WORLD CONFERENCE ON LUNG CANCER 2022
The World Conference on Lung Cancer (WCLC) is the world’s largest international meeting on lung cancer and thoracic oncology, which will be held on August 6~9th 2022. In this exciting gathering of clinicians and researchers, Geneseeq will be sharing a poster discussion and…
July 19, 2022
Geneseeq, Brazilian Hospital Partner on Co-establishment of In-house NGS Lab
Geneseeq is teaming up with Hospital de Base in Sao José do Rio Preto, Brazil to build an NGS-based precision oncology diagnostic lab in-house to advance clinical research and offer comprehensive genetic testing to cancer patients in Brazil. Under the terms of the…
July 5, 2022
Geneseeq and collaborators publish new findings from DECIPHER series, exploring single cfDNA feature-based machine learning model for lung cancer early detection
TORONTO, July 5th 2022 - Lung cancer is a leading cause of cancer-related mortality worldwide, making up 25% of all cancer deaths. Early diagnosis benefits lung cancer patients with better survival. Radiological approaches such as the low-dose computed tomography (LDCT)…
June 13, 2022
Geneseeq Multicancer Early Detection Study Yields Promising Results
TORONTO, June 13, 2022 - Early cancer detection can significantly benefit patients with more effective treatments and better prognosis; the earlier one catches the disease, the better the chances of overall survival. But there are only a few existing early screening tests,…
May 31, 2022
Geneseeq at ASCO 2022
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the most influential clinical oncology meetings and provides a forum for the presentation of clinical trials that can change future practice and research. This year, ASCO will be held from June 3-7…
May 19, 2022
Geneseeq collaborates on another minimal residual disease study in chemoradiotherapy-treated inoperable localized non-small cell lung cancer patients.
TORONTO, May 19th, 2022 - Nearly one-third of non-small cell lung cancer (NSCLC) cases are diagnosed as inoperable localized diseases without surgical options. On top of that, there is no reliable clinical indicator to accurately assess the treatment response of definitive…
April 5, 2022
Geneseeq Presents 9 Posters at AACR 2022
TORONTO, April 5—Geneseeq and collaborators are excited to present nine posters at the American Association for Cancer Research (AACR) 2022 (April 8, 2022, 12:00PM-1:00PM). The AACR is the earliest and largest professional cancer research association in the world, providing…
January 4, 2022
Geneseeq’s cancer early detection study series DECIPHER yield another publication in HEPATOLOGY to explore the performance of cfDNA fragmentomics in liver cancer
TORONTO, January 04, 2022 - Early detection of primary liver cancer (PLC), including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC (cHCC-ICC), is essential for optimal survival of patients. Up-to-date, a fast, affordable, and…
November 22, 2021
Geneseeq announces new publication utilizing ultradeep sequencing technology Automated TTriple Groom sequencing (ATG-seq) to monitor minimal residual disease in postoperative non-small cell lung cancer
TORONTO – Nov 19, 2021 - Radical operation is a standard approach for early/mid-stage lung cancer patients. However, tumor recurrences or metastases may inevitably develop which can lead to treatment failures. Minimal residual disease (MRD), a small number of leftover…
November 11, 2021
Geneseeq Forms Lung Cancer Strategic Partnerships with Takeda and AstraZeneca on the Same Day
TORONTO – NOV 11, 2021 - On November 7th, during the 4th China International Import Expo, Geneseeq was invited by Takeda Pharmaceutical (TSE:4502/NYSE:TAK)(“Takeda”) to participate in the launch ceremony of the Takeda Lung Cancer Diagnosis and Treatment Alliance to sign off…
November 8, 2021
Geneseeq collaborates on research identifying predictive biomarkers for guiding personalized adjuvant treatment in resected EGFR-positive non-small cell lung cancer
TORONTO, November 8, 2021 - Adjuvant treatment with gefitinib, a good alternative to current standard-of-care cisplatin-based chemotherapy for patients with epidermal growth factor receptor (EGFR)-mutant stage II-III non-small-cell lung cancer (NSCLC), prolongs time to…
October 27, 2021
Geneseeq Study Shows High Performance Results in Colorectal Cancer Early Detection
TORONTO, October 26, 2021 - Early detection of colorectal cancer (CRC) is important for improving the survival rate and life quality of patients. However, the performances of current CRC early detection methods are still limited. Geneseeq and Shanghai Fudan University…
October 13, 2021
Geneseeq and Zai Lab Announce Strategic Collaboration to Advance Cancer Drug R&D
TORONTO, Oct. 13, 2021 - Geneseeq Technology Inc. ("Geneseeq") and Zai Lab, Ltd. ("Zai Lab") (Nasdaq: ZLAB)(HKEX: 9688) announce new strategic collaboration in Shanghai, China. The companies will collaborate to facilitate the R&D and commercialization of Zai Lab's…
September 15, 2021
Geneseeq Presents 10 studies on MRD, early cancer detection, cancer diagnosis and cancer biology research at EMSO 2021
The European Society of Medical Oncology Annual Conference (ESMO Conference) is the most prestigious and influential oncology conference in Europe; a global academic exchange platform integrating translational research and interdisciplinary discussions. This year the…
September 8, 2021
Geneseeq Presents ctDNA Early Lung Cancer Detection Data at WCLC
The annual World Conference on Lung Cancer (WCLC) has returned on September 11th – 14th, marking the second time the world’s largest event to bring together researchers and physicians in the field of thoracic oncology and lung cancer virtual. The conference is hosted by The…
August 31, 2021
Geneseeq Study Evaluates ctDNA MRD to Predict Response to Therapy and Assess Prognosis in Locally Advanced Rectal Cancer
TORONTO, August 31 - Currently, there is no reliable clinical indicator to accurately assess the treatment response of neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) patients. Determining whether the nCRT-treated LARC patients should adopt the…
June 24, 2021
Geneseeq works with HUTCHMED and AstraZeneca in MET inhibitor approval for lung cancer patients in China
TORONTO, June 24 - The National Medical Products Administration (NMPA) of China officially granted conditional approval of savolitinib by HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) and AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq: AZN) for the treatment of…
June 17, 2021
Geneseeq Joins Integrated DNA Technologies (IDT) Align Program
TORONTO, June 17 – Geneseeq Technology Inc. (Geneseeq) has joined the IDT Align program by Integrated DNA Technologies, Inc. (IDT), a comprehensive genomics solutions provider, expanding the program’s roster of preferred sequencing providers. The combination of Geneseeq’s…
May 26, 2021
Geneseeq Presenting Data at the American Society of Clinical Oncology Annual Meeting 2021
TORONTO, May 26 - As abstracts submitted for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (4−8 June 2021) have published, Geneseeq is excited to announce give a first glance at key data presented by the company, ahead of clinical oncology’s biggest…
May 18, 2021
Geneseeq study shows ctDNA evaluation in early postoperative phase predicts risk of recurrence in colorectal cancer
Early risk stratification and assessment of adjuvant chemotherapy (ACT) efficacy for localized colorectal cancer (CRC) are still lacking in a large patient cohort with a fast and cost-effective approach. A recent prospective, multicenter study published in the Journal of…
April 27, 2021
Geneseeq and AstraZeneca Collaborate to Build Guangzhou Bio-Diagnostics Innovation Center
We are excited to announce our strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company, to establish a Bio-Diagnostic Innovation Center in Guangzhou, China. The center is expected to initiate an integrative and patient-centric…
April 9, 2021
Geneseeq to Present at American Association for Cancer Research Annual Meeting 2021
TORONTO, April 9 -- The American Association for Cancer Research (AACR) is the earliest and largest professional cancer research association in the world, dedicated to basic cancer science and clinical research. The 2021 AACR annual meeting will be held on April 10-15 and…
March 25, 2021
Genomic Study Uncovers New Biomarkers for the Efficacy of Immunotherapy in Nasopharyngeal Carcinoma (NPC) Patients
Researchers published promising clinical data in the Journal for ImmunoTherapy of Cancer (JITC), from two phases I clinical trials using Anti-PD-1 treatment for 124 Chinese recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) patients. An objective response rate…
March 19, 2021
Lung cancer genomic study reveals timing and origins of local and distant metastases and highlights the importance of early cancer detection
Researchers from Guangdong Lung Cancer Institute worked with Geneseeq Technology Inc (Geneseeq) performed whole-exome sequencing (WES) on primary tumors and metastases of lung cancer patients to take a closer look at the genomic divergence, metastatic drivers, the timing of…
March 16, 2021
Geneseeq Collaborates with Illumina to Develop and Commercialize Comprehensive Cancer In-vitro Diagnostic NGS kit
TORONTO, March 16, 2021, 10:00 ET - Next-generation sequencing (NGS)-based precision oncology provider Geneseeq Technology Inc. (“Geneseeq”), will collaborate with Illumina, Inc. (NASDAQ: ILMN) (“Illumina”) to develop comprehensive in-vitro diagnostic NGS testing kits (IVD…
January 25, 2021
Geneseeq and Collaborators to Present New Clinical Research Data during the 2020 IASLC World Conference on Lung Cancer in Singapore
TORONTO, January 25, 2021,10:00 ET - Geneseeq Technology Inc. (“Geneseeq”), along with our clinical collaborators will be presenting new data at the 2020 IASLC World Conference on Lung Cancer in Singapore, commencing on January 28 to January 31, 2021. During the conference,…
June 2, 2020
Geneseeq to showcase novel translational research at the 2020 AACR Virtual Annual Meeting II
Geneseeq Technology Inc. will be presenting a number of our own and collaborative studies during the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, June 22 to June 24. Geneseeq will present 10 studies in the form of E-posters, detailing…
May 26, 2020
Geneseeq and collaborators to share new clinical research data during the ASCO20 Virtual Scientific Program
Geneseeq Technology Inc., along with our clinical collaborators will present new data at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, which will held from May 29 to May 31. Twenty of our studies have been selected by the ASCO committee,…
June 1, 2019
Geneseeq at ASCO 2019
The American Society of Clinical Oncology (ASCO) Annual Meeting is recognized globally as one of the most influential and comprehensive clinical oncology conferences. Each year, the conference attracts over 40,000 oncologists and oncology researchers from around the world.…
May 13, 2019
New biomarkers to predict patients’ clinical outcomes to ICI therapy in lung cancer
New biomarkers to predict patients’ clinical outcomes to ICI therapy in lung cancer One of the ways cancer cells survive is by suppressing the body’s immune system. Cancer immunotherapy aims to restore immune function in cancer patients, allowing the body’s immune system…
December 1, 2018
Geneseeq and Illumina to Develop Clinical Oncogene Kit
Geneseeq and Illumina to Develop Clinical Oncogene Kit Accelerate the launch of Cancer NGS Testing in China Geneseeq, industry leader in next-generation sequencing (NGS) will collaborate with Illumina, global leader in DNA sequencing and array-based technologies,to develop…
